Lauren Gabriele Banaszak

Lauren Gabriele Banaszak

Auto-generated profile, based on publicly available information

Lauren Gabriele Banaszak

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2013 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
QZQiao Zheng
Qiao Zheng
LBLauren Banaszak
Lauren Banaszak
SFSarah Fracci
Sarah Fracci
DBDiana Basali
Diana Basali
SDSarah M Dunlap
Sarah M Dunlap
OROfer Reizes
Ofer Reizes
Despite new therapies, breast cancer continues to be the second leading cause of cancer mortality in women, a consequence of recurrence and metastasis. In recent years, a population of cancer cells has been identified, called cancer stem cells (CSCs) with self-renewal capacity, proposed to underlie tumor recurrence and metastasis. We previously showed that the adipose tissue cytokine LEPTIN, increased in obesity, promotes the survival of CSCsin vivo. Here, we tested the hypothesis that the leptin receptor (LEPR), expressed in mammary cancer cells, is necessary for maintaining CSC-like and metastatic properties. We silenced LEPR via shRNA lentivirus transduction and determined that the expression of stem cell self-renewal transcription factorsNANOG,SOX2, andOCT4(POU5F1) is inhibited. LEPR-NANOG signaling pathway is conserved between species because we can rescueNANOGexpression in humanLEPR-silenced cells with the mouseLepR. Using a NANOG promoter GFP reporter, we showed thatLEPRis enriched in NANOG promoter active (GFP+) cells. In lineage tracing studies, we showed that the GFP+ cells divide in a symmetric and asymmetric manner.LEPR-silenced MDA-MB-231 cells exhibit a mesenchymal to epithelial transition morphologically, increasedE-CADHERINand decreasedVIMENTINexpression compared with control cells. Finally, LEPR-silenced cells exhibit reduced cell proliferation, self-renewal in tumor sphere assays, and tumor outgrowth in xenotransplant studies. Given the emergence ofNANOGas a pro-carcinogenic protein in multiple cancers, these studies suggest that inhibition ofLEPRmay be a promising therapeutic approach to inhibitNANOGand thereby neutralize CSC functions.

1 November 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
AAAmr A. Arafat
Amr A. Arafat
EREric E. Roselli
Eric E. Roselli
JIJay J. Idrees
Jay J. Idrees
KFKe Feng
Ke Feng
LBLauren Banaszak
Lauren Banaszak
LSLars G. Svensson
Lars G. Svensson

27 February 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CSChristopher M. Sande
Christopher M. Sande
SCStone Chen
Stone Chen
DMDana V. Mitchell
Dana V. Mitchell
PLPing Lin
Ping Lin
DADiana M. Abraham
Diana M. Abraham
DBDaria V. Babushok
Daria V. Babushok
Telomere biology disorders (TBDs) are genetic diseases caused by defective telomere maintenance. TBD patients often develop bone marrow failure and have an increased risk of myeloid neoplasms. To better understand the factors underlying hematopoietic outcomes in TBD, we comprehensively evaluated acquired genetic alterations in hematopoietic cells from 166 pediatric and adult TBD patients. Of these patients, 47.6% (28.8% of children, 56.1% of adults) had clonal hematopoiesis. Recurrent somatic alterations involved telomere maintenance genes (7.6%), spliceosome genes (10.4%, mainly U2AF1 p.S34), and chromosomal alterations (20.2%), including 1q gain (5.9%). Somatic variants affecting the DNA damage response (DDR) were identified in 21.5% of patients, including 20 presumed loss-of-function variants in ataxia-telangiectasia mutated ( ATM ). Using multimodal approaches, including single-cell sequencing, assays of ATM activation, telomere dysfunction-induced foci analysis, and cell-growth assays, we demonstrate telomere dysfunction–induced activation of the ATM-dependent DDR pathway with increased senescence and apoptosis in TBD patient cells. Pharmacologic ATM inhibition, modeling the effects of somatic ATM variants, selectively improved TBD cell fitness by allowing cells to bypass DDR-mediated senescence without detectably inducing chromosomal instability. Our results indicate that ATM-dependent DDR induced by telomere dysfunction is a key contributor to TBD pathogenesis and suggest dampening hyperactive ATM-dependent DDR as a potential therapeutic intervention.

10 November 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
LBLauren G. Banaszak
Lauren G. Banaszak
KSKelcy Smith-Simmer
Kelcy Smith-Simmer
KSKyle Shoger
Kyle Shoger
LLLauren Lovrien
Lauren Lovrien
AMAmy Malik
Amy Malik
JCJane E. Churpek
Jane E. Churpek

1 June 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
LBLauren G. Banaszak
Lauren G. Banaszak
PCPaloma L. Cabral
Paloma L. Cabral
KSKelcy Smith-Simmer
Kelcy Smith-Simmer
AHAyesha Hassan
Ayesha Hassan
MBMatthew Brunner
Matthew Brunner
JCJane E. Churpek
Jane E. Churpek
PURPOSE: Knowledge of an inherited predisposition to myelodysplastic syndrome (MDS) and AML has important clinical implications for treatment decisions, surveillance, and care of at-risk relatives. National Comprehensive Cancer Network (NCCN) guidelines recently incorporated recommendations for germline genetic evaluation of patients with MDS/AML on the basis of personal and family history features, but the practicality of implementing these recommendations has not been studied. METHODS: A hereditary hematology quality improvement (QI) committee was formed to implement these guidelines in a prospective cohort of patients diagnosed with MDS/AML. Referral for germline genetic testing was recommended for patients meeting NCCN guideline criteria. Referral patterns and genetic evaluation outcomes were compared with a historical cohort of patients with MDS/AML. Barriers to evaluation were identified. RESULTS: Of the 90 patients with MDS/AML evaluated by the QI committee, 59 (66%) met criteria for germline evaluation. Implementation of the QI committee led to more referrals for germline evaluation in accordance with NCCN guidelines (31% v 14%, P = .03). However, the majority of those meeting criteria were never referred due to high medical acuity or being deceased or in hospice at the time of QI committee recommendations. Despite this, two (17%) of the 12 patients undergoing genetic testing were diagnosed with a hereditary myeloid malignancy syndrome. CONCLUSION: Current NCCN guidelines resulted in two thirds of patients with MDS/AML meeting criteria for germline evaluation. A hereditary hematology-focused QI committee aided initial implementation and modestly improved NCCN guideline adherence. However, the high morbidity and mortality and prolonged inpatient stays associated with MDS/AML challenged traditional outpatient genetic counseling models. Further improvements in guideline adherence require innovating new models of genetic counseling and testing for this patient population.

24 May 2023 in Leukemia Research
Verified
Journal Article
Closed access
RBRory Bade
Rory Bade
LBLauren G. Banaszak
Lauren G. Banaszak
FOFauzia Osman
Fauzia Osman
PCPaloma Cabral
Paloma Cabral
AHAyesha Hassan
Ayesha Hassan
RMRyan J. Mattison
Ryan J. Mattison